DK0444186T4 - Farmaceutisk præparat, som gør celler, der udtrykker MHC klasse II-antigener, til mål for cytotoksiske T-celler - Google Patents

Farmaceutisk præparat, som gør celler, der udtrykker MHC klasse II-antigener, til mål for cytotoksiske T-celler

Info

Publication number
DK0444186T4
DK0444186T4 DK90914564T DK90914564T DK0444186T4 DK 0444186 T4 DK0444186 T4 DK 0444186T4 DK 90914564 T DK90914564 T DK 90914564T DK 90914564 T DK90914564 T DK 90914564T DK 0444186 T4 DK0444186 T4 DK 0444186T4
Authority
DK
Denmark
Prior art keywords
cells
cytotoxic
antigens
mhc class
expressing mhc
Prior art date
Application number
DK90914564T
Other languages
English (en)
Other versions
DK0444186T3 (da
Inventor
Terje Kalland
Gunnar Hedlung
Mikael Dohlsten
Peter Lando
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20376934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0444186(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Application granted granted Critical
Publication of DK0444186T3 publication Critical patent/DK0444186T3/da
Publication of DK0444186T4 publication Critical patent/DK0444186T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK90914564T 1989-09-20 1990-09-14 Farmaceutisk præparat, som gør celler, der udtrykker MHC klasse II-antigener, til mål for cytotoksiske T-celler DK0444186T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8903100A SE8903100D0 (sv) 1989-09-20 1989-09-20 New pharmaceutical agent
PCT/SE1990/000592 WO1991004053A1 (en) 1989-09-20 1990-09-14 Pharmaceutical composition that makes cells expressing mhc class ii antigens targets for cytotoxic t-cells

Publications (2)

Publication Number Publication Date
DK0444186T3 DK0444186T3 (da) 1996-01-02
DK0444186T4 true DK0444186T4 (da) 2003-11-24

Family

ID=20376934

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90914564T DK0444186T4 (da) 1989-09-20 1990-09-14 Farmaceutisk præparat, som gør celler, der udtrykker MHC klasse II-antigener, til mål for cytotoksiske T-celler

Country Status (8)

Country Link
EP (1) EP0444186B2 (da)
JP (1) JP3147237B2 (da)
AT (1) ATE130199T1 (da)
DE (1) DE69023635T3 (da)
DK (1) DK0444186T4 (da)
ES (1) ES2079489T5 (da)
SE (1) SE8903100D0 (da)
WO (1) WO1991004053A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6126945A (en) 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
WO1991006319A1 (en) * 1989-10-27 1991-05-16 Arch Development Corporation Methods and compositions for promoting immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
EP1129717B2 (en) * 1990-01-17 2013-03-06 TERMAN, David S. Use of homologues of staphylococcal enterotoxins for cancer treatment
US5858363A (en) * 1990-07-20 1999-01-12 Pharmacia & Upjohn Ab Target specific antibody-superantigen conjugates and their preparation
SE9002484L (sv) 1990-07-20 1992-01-21 Kabi Pharmacia Ab Nya substituerade polyetrar
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
WO1996014744A1 (en) * 1994-11-14 1996-05-23 National Jewish Center For Immunology And Respiratory Medicine Protective effects of mutated superantigens
US5935568A (en) * 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
WO2007009064A2 (en) 2005-07-11 2007-01-18 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
SG177907A1 (en) 2006-06-14 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689222A (en) * 1985-01-18 1987-08-25 Mcmichael John Methods and materials for alleviation of pain symptoms of malignant neoplasia
DK528285D0 (da) * 1985-11-15 1985-11-15 Novo Industri As Peptider samt praeparater indeholdende disse
SE8801426D0 (sv) * 1988-04-15 1988-04-15 Ulf Rothman Forfarande och medel for blodbehandling
EP1129717B2 (en) † 1990-01-17 2013-03-06 TERMAN, David S. Use of homologues of staphylococcal enterotoxins for cancer treatment

Also Published As

Publication number Publication date
DE69023635T3 (de) 2004-06-03
DE69023635T2 (de) 1996-06-20
WO1991004053A1 (en) 1991-04-04
EP0444186A1 (en) 1991-09-04
EP0444186B2 (en) 2003-10-29
EP0444186B1 (en) 1995-11-15
DK0444186T3 (da) 1996-01-02
JP3147237B2 (ja) 2001-03-19
DE69023635D1 (de) 1995-12-21
JPH04505767A (ja) 1992-10-08
ES2079489T5 (es) 2004-05-16
SE8903100D0 (sv) 1989-09-20
ES2079489T3 (es) 1996-01-16
ATE130199T1 (de) 1995-12-15

Similar Documents

Publication Publication Date Title
DK0444186T3 (da) Farmaceutisk præparat, som gør celler, der udtrykker MHC klasse II-antigener, til mål for cytotoksiske T-celler
Ohishi Activation of botulinum C2 toxin by trypsin
ES2088873T3 (es) Celulas dotadas con especialidad de anticuerpos.
NO914206L (no) Terapeutisk middel
WO1995016038A3 (en) Humanized antibodies and uses thereof
IL77293A (en) Stable,covalently-coupled,polysaccharide-protein conjugates comprising neutral polysaccharides and immunogenic proteins coupled through bigeneric spacers,methods for preparing them and pharmaceutical compositions containing them
ES2112838T3 (es) Peptidos receptores de celulas t como agentes terapeuticos para enfermedades autoinmunitarias y malignas.
DK0957935T3 (da) Chlamydia-vacciner og immunogene præparater indeholdende et ydre membran-antigen samt fremgangsmåde til fremstilling deraf
BR9809445A (pt) Polipeptìdeo compreendendo uma porção imunogênica de um antìgeno de m. tubercolosis, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica, vacina, proteìna de fusão, processos para indução de imunidade protetora em um paciente, processo de detecção de tuberculose em um paciente,e , kit de diagnóstico.
AU1618499A (en) Oxygen-transporting albumin-based blood replacement composition and blood volumeexpander
DE69122240D1 (de) Antigen-wirkende proteine von borrelia burgdorferi
ATE220688T1 (de) Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
BRPI0411510A (pt) proteìna, composição farmacêutica, uso da proteìna, polipeptìdeo, uso do mesmo, vetor, ácido nucleico, célula hospedeira, soro policlonal, anticorpo monoclonal, uso de um soro policlonal ou de um anticorpo monoclonal, método para alvejar in vitro uma molécula de interesse com as células que expressam cd11b, células que expressam cd11b, produto de terapia celular para imunizar um ser humano ou um animal contra um antìgeno uso de células que expressam cd11b, e, método para imunizar um paciente contra antìgeno
BR9509172A (pt) Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica
SE8008096L (sv) Sett att binda ett protein till en berare innehallande hydroxylgrupper
AR029624A1 (es) Anticuerpos o fragmentos de anticuerpos anti-idiotipicos recombinantes y composicion farmaceutica que los contiene
EP0992584A3 (en) Purified mammalian FLT3 ligands and agonists and antagonists thereof
GR3007031T3 (da)
Ohta et al. Characterization of a cell-surface protein antigen of hydrophilic Streptococcus mutans strain GS-5
AU7556487A (en) Immunotoxins, process for their preparation and pharmaceutical compositions in which they are present
DE69524971D1 (de) Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen
Dubreuil et al. Purification, and biochemical and structural characterization of a fimbrial haemagglutinin of Renibacterium salmoninarum
Spero et al. Mitogenicity of formalinized toxoids of staphylococcal enterotoxin B
Schmidt et al. Interaction of streptococcal cell wall components with fibrinogen. I. Adsorption of fibrinogen by immobilized T-proteins of Streptococcus pyogenes
SE9300139L (sv) Framställning av ett nytt läkemedel